Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says

(By Ed Silverman for STAT)

The newly approved1 Sarepta Therapeutics drug for Duchenne muscular dystrophy2 will cost about $300,000 a year for the average patient in the United States, which is less than what some Wall Street analysts had expected.  Continue reading article here……

stat-logo

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.